What is August?
August distinguishes itself through a dual-focus business model that bridges the gap between high-level scientific inquiry and professional service delivery. By specializing in the modulation of specific biological pathways and cellular expansion, the company provides critical tools and compounds for the global scientific community. Beyond its core research-driven product suite, August maintains a unique operational footprint that includes event-based hospitality services, creating a multifaceted enterprise that serves both laboratory professionals and event organizers. This hybrid approach allows the firm to leverage its scientific expertise while maintaining a diverse revenue stream, positioning it as a versatile player in the competitive biotechnology and research services landscape.
How much funding has August raised?
August has raised a total of $156K across 1 funding round:
Debt
$156K
Debt (2026): $156K with participation from Live Oak Bank
Key Investors in August
Live Oak Bank
A specialized financial institution known for providing debt capital and banking services to small businesses and high-growth companies across various sectors, including technology and healthcare.
What's next for August?
With the successful acquisition of this debt-based financing, August is expected to prioritize the optimization of its research infrastructure and the expansion of its cellular modulation product lines. The strategic deployment of these funds will likely focus on enhancing laboratory capabilities to meet the increasing demand for specialized research compounds. Furthermore, the company is poised to refine its operational efficiency, ensuring that its dual-service model remains sustainable as it scales. By leveraging this capital, August aims to solidify its market position, potentially accelerating the development of new therapeutic pathways and expanding its reach within the professional scientific sector.
See full August company page